Literature DB >> 16937175

Cardiorespiratory effects induced by vagus nerve stimulation in epileptic children.

Mickael Pruvost1, Boubker Zaaimi, Reinhard Grebe, Fabrice Wallois, Patrick Berquin, Volker Perlitz.   

Abstract

Vagus nerve stimulation (VNS) is used in pharmaco-resistant epilepsy to decrease the number of seizures. Although it is well known that VNS affects respiration, there are only a few reports concerning an effect of VNS on heart rate or heart rate variability (HRV). We investigated the relationship between respiratory frequency and the high frequency (HF) domain of the discrete Fourier transform (DFT) of the RR interval function during night sleep recordings of ten subjects treated with VNS. Our results show that VNS shifts the frequency of maximal power spectrum density (PSD) in the HF-band, decreases the related PSD and induces a partial cardiorespiratory decoupling.

Entities:  

Mesh:

Year:  2006        PMID: 16937175     DOI: 10.1007/s11517-006-0041-5

Source DB:  PubMed          Journal:  Med Biol Eng Comput        ISSN: 0140-0118            Impact factor:   2.602


  22 in total

1.  Nonstationary time-series analysis applied to investigation of brainstem system dynamics.

Authors:  R Vandenhouten; M Lambertz; P Langhorst; R Grebe
Journal:  IEEE Trans Biomed Eng       Date:  2000-06       Impact factor: 4.538

2.  Left vagus nerve stimulation with the neurocybernetic prosthesis has complex effects on heart rate and on its variability in humans.

Authors:  M G Frei; I Osorio
Journal:  Epilepsia       Date:  2001-08       Impact factor: 5.864

3.  Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.

Authors: 
Journal:  Eur Heart J       Date:  1996-03       Impact factor: 29.983

4.  Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control.

Authors:  S Akselrod; D Gordon; F A Ubel; D C Shannon; A C Berger; R J Cohen
Journal:  Science       Date:  1981-07-10       Impact factor: 47.728

5.  Respiratory sinus arrhythmia is a limited measure of cardiac parasympathetic control in man.

Authors:  M Kollai; G Mizsei
Journal:  J Physiol       Date:  1990-05       Impact factor: 5.182

6.  Vagus nerve stimulation in 15 children with therapy resistant epilepsy; its impact on cognition, quality of life, behaviour and mood.

Authors:  Tove Hallböök; Johan Lundgren; Karin Stjernqvist; Gösta Blennow; Lars-Göran Strömblad; Ingmar Rosén
Journal:  Seizure       Date:  2005-09-19       Impact factor: 3.184

7.  High strength stimulation of the vagus nerve in awake humans: a lack of cardiorespiratory effects.

Authors:  A P Binks; D Paydarfar; S C Schachter; A Guz; R B Banzett
Journal:  Respir Physiol       Date:  2001-09

8.  A quantitative study of gamma-band activity in human intracranial recordings triggered by visual stimuli.

Authors:  J P Lachaux; E Rodriguez; J Martinerie; C Adam; D Hasboun; F J Varela
Journal:  Eur J Neurosci       Date:  2000-07       Impact factor: 3.386

9.  Brain natriuretic peptide-like immunoreactive innervation of the cardiovascular and cerebrovascular systems in the rat.

Authors:  C B Saper; M R Kibbe; K M Hurley; S Spencer; H R Holmes; K M Leahy; P Needleman
Journal:  Circ Res       Date:  1990-12       Impact factor: 17.367

10.  Vagus nerve stimulation for drug-resistant epilepsy in children and young adults.

Authors:  Sabrina Buoni; Aldo Mariottini; Sergio Pieri; Alessandro Zalaffi; Maria Angela Farnetani; Mirella Strambi; Lucio Palma; Alberto Fois
Journal:  Brain Dev       Date:  2004-04       Impact factor: 1.961

View more
  1 in total

Review 1.  Non-respiratory indications for polysomnography and related procedures in children: an evidence-based review.

Authors:  Suresh Kotagal; Cynthia D Nichols; Madeleine M Grigg-Damberger; Carole L Marcus; Manisha B Witmans; Valerie G Kirk; Lynn A D'Andrea; Timothy F Hoban
Journal:  Sleep       Date:  2012-11-01       Impact factor: 5.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.